Abstract
Papillary thyroid cancer (PTC) is the most common pathological type of thyroid cancer, and its morbidity raises rapidly in the global world. V-raf murine sarcoma viral oncogene homolog B1 (BRAF)V600E mutation and telomerase reverse transcriptase (TERT) promoter mutations are the most common molecular markers of PTC. Nowadays, more and more studies find that the coexistence of BRAFV600E and TERT promoter mutations plays a synergistic role in the invasion and prognosis of PTC. This article reviews the recent advance in the synergism of BRAFV600E and TERT promoter mutations in PTC. Key words: Thyroid neoplasms; Mutation; Proto-oncogene proteins B-raf; Telomerase; Trends
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Nuclear Medicine and Molecular Imaging
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
